BSPGHAN DISTINGUISHED SERVICE AWARD closing date for 2021 nominations: October 7th 2021

BSPGHAN Council are delighted to announce that BSPGHAN will be offering an Annual Award to recognize a member* who has made a major contribution to paediatric gastroenterology, hepatology or nutrition. The award will be given at the Annual Meeting and is to recognise and celebrate an individual’s accomplishment within their  career  or recent  achievements.  

A call for nominations will be advertised on the BSPGHAN website  in September  each year.  

Please download the full details for eligibility, standards, criteria and selection process.

*A Full or Associate member of BSPGHAN for at least 5 years at the time of nomination.  

Please remember that Honorary Membership may also be conferred by the Society, at the recommendation of Council, upon distinguished colleagues who have made an outstanding contribution to paediatric gastroenterology, whether they be members of the Society or not. Upon retirement, Full Members may apply in writing to the Convenor to become Honorary Members. Honorary Members are not be required to pay the annual subscription fee and do not have voting rights at the Annual General Meeting nor at Special Meetings. 

Best wishes

Sue Protheroe 

President of BSPGHAN 18/8/21 

Updated JCVI Guidance –  Covid vaccination of children and young people aged 12- 17 years

Updated JCVI Guidance – Covid vaccination of children and young people aged 12- 17 years

Dear members

Please see updated Guidance from the JCVI

in addition to previous advice

At this time,

  • the Pfizer-BioNTech BNT162b2 vaccine is the only vaccine authorised for persons aged 12 to 17 years in the UK
  • JCVI advises that all 16 to 17-year-olds should be offered a first dose of Pfizer-BNT162b2 vaccine. 
  • Persons aged 12 to 15 years with specific underlying health conditions that put them at risk of severe COVID-19, should be offered 2 doses of Pfizer-BNT162b2 vaccine with an interval of 8 weeks between doses.

This currently includes children with severe neuro-disabilities, Down’s Syndrome, underlying conditions resulting in immunosuppression, profound and multiple learning disabilities (PMLD), severe learning disabilities or who are on the learning disability register. Details regarding additional person-groups with underlying health conditions to be offered vaccination will be provided as updates in the Green Book.

Children and young people aged 12 years and over who are household contacts of persons (adults or children) who are immunosuppressed should be offered 2 doses of Pfizer-BNT162b2 vaccine.

The rollout of Covid vaccination in England will be led through primary care. The letter notes: “We recognise that not all eligible 12-15 year olds may be identified through the GP record. Therefore, any approach by parents of children at increased risk should be considered and clinical judgement used around eligibility in line with JCVI advice. In addition, trusts may refer 12-15 year olds for a COVID-19 vaccination if they consider them to be eligible”

Letter to primary care –

FAQs on Vaccination delivery operations

Best wishes


Dr S Protheroe
BSPGHAN President

Environmental Enteropathy- Paul Kelly

Environmental Enteropathy- Paul Kelly

BSPGHAN Education Series Videos

Environmental Enteropathy- Paul Kelly

This is a recording of the the CAPGAN/ BSPGHAN webinar delivered by Professor Paul Kelly, Professor of Tropical Gastroenterology at Barts & The London School of Medicine, UK on 1 July 2021. Produced by KYL.

RCPCH COVID Vaccination Update

The College has recently updated its webpage on the COVID-19 vaccine programme with some FAQs. This is available alongside advice for paediatricians published earlier this year on the eligibility of children and young people for COVID-19 vaccines in phase 1 of the programme. We're continuing to monitor these issues and will update the FAQ page as the situation develops.

With best wishes,

Kate Webb
Health Policy Lead
Royal College of Paediatrics and Child Health

Open letter to Matt Hancock from IBD UK

Open letter to Matt Hancock from IBD UK

Dear Members

IBD UK will be sharing this open letter to Matt Hancock on the IBD UK website and Crohn’s & Colitis UK website on Monday morning. We will then be sharing it on social media channels with the attached graphic and copy below, which you are welcome to use in your own posts if you are planning on sharing the letter.


The @IBDUKTEAM report showed that IBD care across the UK needs to change. IBD needs to be taken seriously, so we’re asking @MattHancock for a clear government strategy for improvement. Please RT and support our ask for #BetterIBDCare


The IBD UK report showed that IBD care across the UK needs to change. IBD needs to be taken seriously, so we’re asking @matthancockofficial for a clear government strategy for improvement. Please share and support our ask for #BetterIBDCare

Best wishes.



Crohn’s and Colitis UK acting as Secretariat to IBD UK

Tel No: 01727 734471


Follow us on Twitter: @IBDUKTEAM

Updated JCVI advice on Covid19 vaccines for adults aged under 30 years

Updated JCVI advice on Covid19 vaccines for adults aged under 30 years

Covid19 Vaccination update 7th April 2021

(replaces advice on BSPGHAN website on 31st January 2021)

Today, April 7th, 2021, the Joint Committee on Vaccination and Immunisation (JCVI) has changed their clinical advice on Covid 19 vaccines for those aged under 30 years.  

Adults aged 18 to 29 who do not have an underlying health condition that puts them at greater risk from Covid should be offered an alternative to the Astra Zeneca vaccine if one is available.

The MHRA advised that-

  • side-effects were "extremely rare" - and more work was going on to identify if the Astra Zeneca vaccine was causing blood clots.
  • People who have had their first dose of the AstraZeneca vaccine should still get their second dose. 
  • Only those who suffered one of these rare blood clots after the first dose should not get vaccinated.
  • People with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor.
  • The JCVI today said that they have not made a  decision yet  (on vaccine advice) on those aged under 18 years.

The Pfizer/BioNTech vaccine is authorised for use in individuals aged 16 years and over, and the Oxford/AstraZeneca vaccine is authorised for individuals aged 18 years and over. 

Also see that here that the RCPCH updated their advice on 29th March 2021, for paediatricians on children and young people and the COVID-19 vaccination programme

This advice may be updated in light of the announcement today.

We are now in the first phase of the programme during which young people (aged 16 years and over) with specific clinical vulnerabilities will be offered vaccination.1   ( Based on JCVI advice, individuals aged 16–65 years in at-risk groups are eligible for immunisation in Phase 1 of the programme).

The Green Book says: “Children and young people have a very low risk of COVID-19, severe disease or death due to SARS-CoV-2 compared to adults and so COVID-19 vaccines are not routinely recommended for children and young people under 16 years of age. Children under 16 year of age, even if they are CEV, are at low risk of serious morbidity and mortality, and, given the absence of safety and efficacy data on the vaccine, are not recommended for vaccination.” 2

While this is the case, vaccinations should not be offered to children and young people who fall outside the categories advised by the JCVI and the Green Book.  

The only other group identified by the Joint Committee on Vaccination and Immunisation (JCVI) and the Green Book3 that may be considered for the vaccine during phase 1 are:

  • older children (aged 12 years and over) with severe neuro-disabilities and recurrent respiratory tract infections who frequently spend time in specialised residential care settings for children with complex needs.

Such vaccinations would be considered unlicensed use.4 Paediatricians should discuss the benefits and risks and limited safety data with children, young people and their parents/guardians. Any vaccination would need to be authorised by a prescriber (usually a doctor). We would expect that this discussion would take into account: 

  • the frequency and severity of respiratory infection, and
  • the history of hospital admissions, particularly the risk of or previous admissions to paediatric intensive care due to respiratory tract infections.

It is important to stress that at this time the JCVI consider that there are no data to support use of the vaccine in younger age groups or other clinical groups.

Sue Protheroe
BSPGHAN President April 7th 2021

March 2021 Highlights

March 2021 Highlights

Dear members 

I hope this email finds you all well. 

I trust that you are looking forward to our BSPGHAN Annual Meeting 27-29th April. If you already registered for January, there's no need to re-register for April.  A reminder that accepted abstracts will be published in Frontline Gastroenterology.

I hope that you are making regular use of your access to the journal and enjoying the brilliant educational material that is accessed via our members login page? 

Please see Highlights for Members – Publishing Papers to Impact on Practice for March 2021 sent from the Editor in Chief, Professor Mark Beattie.  

Best wishes 

Sue  BSPGHAN President. 

Dear Colleagues 

I wanted to highlight some of our recent published content that I thought would be of interest 

The gut microbiome: what every gastroenterologist needs to know

Getting to grips with sarcopenia: recent advances and practical management for the gastroenterologist

Diagnostic ileocolonoscopy: getting the basics right

Refeeding syndrome : physiological background and practical management

British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding

Also online first

How to manage a high-output stoma

Short bowel syndrome in infancy: recent advances and practical management

Gut-focused hypnotherapy for children and adolescents with irritable bowel syndrome

Exit strategies from the COVID-19 lockdown for children and young people receiving home parenteral nutrition (HPN): lessons from the BSPGHAN Intestinal Failure Working Group experience

Eosinophilic oesophagitis: recent advances and practical management

Check out the journal – lots of other excellent content across gastroenterology, endoscopy, hepatology and nutrition

Follow us on twitter

Check out the blog

Listen to our regular podcasts

Check out the instructions for authors – send us your best work – pre submission enquiries welcome

Mark Beattie 

Professor RM Beattie

Consultant Paediatric Gastroenterologist

Honorary Professor of Paediatric Gastroenterology and Nutrition

Editor in Chief Frontline Gastroenterology


Contact Us  l  Privacy Policy  l  Members Login  

© 2021 British Society of Paediatric Gastroenterology, Hepatology and Nutrition  l Charity Number 299294 l VAT registration number 323665308
Website design and development by KYL.